Xiao Kang Liu
Direttore/Membro del Consiglio presso PharmaLegacy Laboratories (Shanghai) Co., Ltd.
Profilo
Xiao Kang Liu is a graduate of Nanjing University.
Currently, he is a Member-Supervisory Board at PharmaLegacy Laboratories (Shanghai) Co., Ltd.
Posizioni attive di Xiao Kang Liu
Società | Posizione | Inizio |
---|---|---|
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Direttore/Membro del Consiglio | 01/04/2020 |
Formazione di Xiao Kang Liu
Nanjing University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Commercial Services |
- Borsa valori
- Insiders
- Xiao Kang Liu